Resalis Therapeutics

Did you miss our presentation at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society? Resalis' CSO, Riccardo Panella, took the stage to share exciting insights into our latest advancements in oligonucleotide therapeutics. We’re proud to be at the forefront of regulating gene expression to tackle challenges in weight management. Here’s a glimpse of Riccardo in action at the event! Stay tuned for more updates as we continue driving innovation in this field.

November is Diabetes Awareness Month, a time to recognize the many challenges faced by those living with diabetes and to focus on improving care. In doing so, it’s important to acknowledge the broader impact of diabetes on overall health. Here are a few lesser-known connections that deserve attention this month: ⬤ 𝐒𝐥𝐞𝐞𝐩 𝐏𝐚𝐭𝐭𝐞𝐫𝐧𝐬: Poor sleep can make managing diabetes more challenging. Lack of sleep can increase insulin resistance, making it harder for the body to regulate blood sugar levels. This creates a cycle that can be difficult to break. ⬤ 𝐌𝐞𝐧𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡: The daily management of diabetes often brings stress and anxiety, which in turn can affect blood glucose levels. Stress hormones like cortisol can increase blood sugar, adding another layer of complexity to diabetes care. ⬤ 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐇𝐞𝐚𝐥𝐭𝐡: Diabetes significantly increases the risk of cardiovascular diseases, such as heart disease and stroke. Elevated blood glucose levels can damage blood vessels over time, making heart health a critical area of focus for people with diabetes. We recognize that addressing diabetes requires a deeper understanding of these interconnected challenges. Our work with RES-010 focuses on targeting the miR-22 pathway, aiming to improve metabolic regulation at its source. By addressing the underlying metabolic pathways that contribute to conditions like obesity, we aim to reduce the risk factors for type 2 diabetes and disease-related complications. This approach offers the potential for more effective prevention and long-term management, aligning with the goal of improving overall well-being for those at risk of or living with diabetes. References: Cureus. 2023 Nov 3;15(11):e48228; The relationship between sleep and type 2 diabetes. https://lnkd.in/dFka_8J - Stress and diabetes management. https://lnkd.in/dSuUP5h - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) https://lnkd.in/gWm9Zju - Centers for Disease Control and Prevention; Diabetes and your heart. #DiabetesAwarenessMonth #MetabolicHealth

November is Diabetes Awareness Month, and World Diabetes Day on November 14 serves as a global reminder of the need for innovation in managing metabolic health. In 2024, the theme centers on "Diabetes and Well-being," emphasizing the importance of supporting both physical and mental health for individuals living with diabetes. We share this vision by focusing on therapies that address the metabolic complexities of diabetes, aiming to improve overall well-being through targeted research and innovative approaches like our lead candidate, RES-010. RES-010 represents a novel approach as an anti-miR-22 therapy, designed to address the complex pathways that contribute to obesity, which can lead to type 2 diabetes, and other metabolic disorders. As we recognize the impact of diabetes on millions of individuals worldwide, we remain dedicated to advancing research and developing therapies aimed at transforming metabolic disease management. Let’s use this month to amplify conversations around metabolic health and the importance of scientific progress in creating a healthier future. #WorldDiabetesDay #DiabetesMonth 

Our CEO, Alessandro Toniolo, is heading to Stockholm to attend #BIOEurope 2024 on November 4-6. This event is Europe’s premier biotech partnering conference, gathering industry leaders, innovators, and visionaries to foster partnerships and explore new growth opportunities. Alessandro is looking forward to connecting with global partners for updates on our mission of tackling obesity with a non-coding RNA.

No tricks, just exciting treats this Halloween! #ICYMI: Earlier this week, we announced a strategic equity investment from Sanofi, and now we’re more energized than ever to accelerate the development of our lead antisense oligonucleotide, RES-010, targeting miR-22. This innovative therapeutic candidate has the potential to redefine obesity treatment by addressing the root causes of the metabolic disorder, not just the symptoms. Stay tuned—no spooky surprises, only great science ahead!

We started 2024 by announcing a successful Series A financing, and now we have even more exciting news to share! Resalis has secured a strategic equity investment from Sanofi, which will drive the development of our lead candidate, RES-010, a first-in-class antisense oligonucleotide targeting miR-22, through a Phase 2 proof-of-concept clinical trial. This innovative approach is designed to reprogram metabolic pathways by increasing energy expenditure instead of suppressing appetite, thereby offering potential sustained fat loss and tackling obesity at its core.

As we recognize Health Literacy Month and National Health Education Week, Resalis is raising awareness about the importance of health education. This week, we highlight the crucial role of education in promoting better health outcomes, especially in metabolic diseases. Understanding the root causes of metabolic conditions and innovative treatment approaches allows for more informed decisions and research. At Resalis, we are advancing our lead candidate, RES-010, which targets a master regulator of multiple pathways underlying metabolic diseases, offering a disease-modifying therapeutic impact for long-term weight management and reduction of hepatic steatosis. Health literacy empowers individuals and healthcare professionals to explore these advanced treatment options. This month, and every month, we remain committed to educating our community. Follow our posts to stay updated on the latest metabolic disease research at Resalis. #NationalHealthEducationWeek #HealthLiteracyMonth

Did you know that understanding obesity is key to unlocking better health outcomes? This Health Literacy Month, Resalis is highlighting the importance of being informed about metabolic diseases like obesity—a critical first step in improving health outcomes. Health literacy means having the knowledge to understand a condition, making informed decisions, and managing health as effectively as possible. When it comes to metabolic disorders like obesity, this understanding is vital. Obesity is a complex disease influenced by multiple factors. Managing body weight often requires a variety of approaches. While lifestyle changes like diet and exercise are commonly recommended, it's important to recognize that effective strategies can vary significantly between individuals. But did you know that underlying biological mechanisms also play a key role? At Resalis, we’re developing RES-010 to target miR-22, a key regulator of fat metabolism. By addressing the root causes of obesity, we aim to offer more durable and effective treatments. As part of our commitment to health education, we release a new monthly post to inform the community about our research, the metabolic diseases we’re addressing, and the science driving our innovations. With greater education and research, we can reshape the future of treating metabolic disorders. #HealthLiteracyMonth #Obesity #WeightManagement

Congratulations to Victor Ambros and Gary Ruvkun on being awarded The Nobel Prize 2024 in Physiology or Medicine for the discovery of microRNA and its role in post-transcriptional gene regulation. This recognition underscores the profound impact microRNA can have on how organisms develop and function. Their work has paved the way for new approaches to therapeutic intervention based on gene regulation pathways. At Resalis, we have elucidated the central role of a microRNA, miRNA-22 (miR-22), which is involved in a range of molecular pathways underlying metabolic disorders. As one of the few experts in the field tackling obesity with miRNAs, we have designed our lead candidate, RES-010, an antisense oligonucleotide (ASO) that targets miR-22, to be a safe and convenient treatment with durable, disease-modifying therapeutic impact. By advancing RES-010, we build on the foundation set by these seminal discoveries, aiming to bring transformative therapies to those affected by metabolic conditions. #NobelPrize #microRNA

Resalis’ CSO, Riccardo Panella, will attend the 20th Annual Meeting of the Oligonucleotide Therapeutics Society from October 6-9 in Montreal. This global event brings together scientists, researchers, and industry leaders dedicated to advancing oligonucleotide therapeutics. Riccardo will participate in presentations, panel discussions, poster sessions, and networking opportunities, engaging with experts in this rapidly evolving field focused on using short DNA or RNA molecules to regulate gene expression. #OTS2024 #OTS24 #OligoMeeting